Molecular profiling of single circulating tumor cells with diagnostic intention by Polzer, Bernhard et al.
Research Article
Molecular profiling of single circulating tumor cells
with diagnostic intention
Bernhard Polzer1,†, Gianni Medoro2,†, Sophie Pasch3, Francesca Fontana2, Laura Zorzino4, Aurelia
Pestka5, Ulrich Andergassen5, Franziska Meier-Stiegen6, Zbigniew T Czyz1,3, Barbara Alberter1, Steffi
Treitschke1, Thomas Schamberger3, Maximilian Sergio2, Giulia Bregola2, Anna Doffini2, Stefano Gianni2,
Alex Calanca2, Giulio Signorini2, Chiara Bolognesi2, Arndt Hartmann7, Peter A Fasching8, Maria T
Sandri4, Brigitte Rack5, Tanja Fehm6, Giuseppe Giorgini2, Nicolò Manaresi2,‡ & Christoph A Klein1,3,*,‡
Abstract
Several hundred clinical trials currently explore the role of circulat-
ing tumor cell (CTC) analysis for therapy decisions, but assays
are lacking for comprehensive molecular characterization of CTCs
with diagnostic precision. We therefore combined a workflow for
enrichment and isolation of pure CTCs with a non-random whole
genome amplification method for single cells and applied it to 510
single CTCs and 189 leukocytes of 66 CTC-positive breast cancer
patients. We defined a genome integrity index (GII) to identify
single cells suited for molecular characterization by different
molecular assays, such as diagnostic profiling of point mutations,
gene amplifications and whole genomes of single cells. The reliabil-
ity of > 90% for successful molecular analysis of high-quality
clinical samples selected by the GII enabled assessing the molecu-
lar heterogeneity of single CTCs of metastatic breast cancer
patients. We readily identified genomic disparity of potentially
high relevance between primary tumors and CTCs. Microheteroge-
neity analysis among individual CTCs uncovered pre-existing cells
resistant to ERBB2-targeted therapies suggesting ongoing micro-
evolution at late-stage disease whose exploration may provide
essential information for personalized treatment decisions and
shed light into mechanisms of acquired drug resistance.
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Introduction
Cancer is an evolutionary process where differences in microenvi-
ronmental selection pressures, iatrogenic intervention and dynamic
cellular changes over time constantly generate variant subpopula-
tions among systemically spread cancer cells (Greaves & Maley,
2012; Klein, 2013). The need to monitor these changes is growing
from the recent re-appreciation of the heterogeneity among tumor
cells (Gerlinger et al, 2012) and the great promise of targeted thera-
pies. Such therapies exploit specific molecular characteristics of the
cancer cells (Luo et al, 2009); however, heritable genetic and epi-
genetic changes as well as phenotypic plasticity of the cancer cells
often result in acquired drug resistance. Moreover, prolonged
disease courses as a consequence of several lines of treatment inevi-
tably lead to the evolution of cancer cells that are increasingly dispa-
rate from the primary tumor that was surgically removed long time
ago. Hence, primary tumors become less relevant sources of molec-
ular information about systemically spread cancer cells and moni-
toring cancer evolution over disease courses would be important.
However, this is seldom performed. The major reason for this is that
repeated intralesional bioptic sampling is rarely tolerable for the
patients and often not feasible. Therefore, many clinical studies
currently explore the use of circulating tumor cells (CTCs) as a
“liquid biopsy”.
Recent technologies for the enrichment and detection of CTCs
have shown an association of CTC counts with clinical outcome in
breast (Cristofanilli et al, 2004; Liu et al, 2009; Bidard et al, 2014)
and other cancers (Danila et al, 2007; Cohen et al, 2008). Here,
the FDA-cleared Cell Search system (Veridex LLC) has become the
gold standard (Cristofanilli et al, 2005; de Bono et al, 2008; Cohen
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et al, 2008). As metastatic tissue is often inaccessible and substan-
tial heterogeneity has been shown between both the primary tumor
and its metastases as well as between different metastases of an
individual patient (Stoecklein & Klein, 2010; Almendro et al, 2014),
molecular CTC analysis could serve as an easily accessible liquid
biopsy for metastatic disease. Additionally, repeated sampling and
molecular analysis of CTCs could help to uncover traits of cancer
cells selected under therapy early on and could enable physicians to
rapidly adapt treatment strategies.
However, two major obstacles have limited the exploitation of
CTC analysis, first the isolation of individual tumor cells to purity
without contaminating white blood cells (WBCs) and second, the
ability to comprehensively analyze single cell genomes or pheno-
types for diagnostic purposes. We addressed these two problems by
combining a novel cell-sorting microsystem based on dielectropho-
resis (Manaresi et al, 2003) with a deterministic single cell amplifi-
cation method (Klein et al, 1999). The DEPArrayTM technology
(Silicon Biosystems SpA) enables automated isolation of pure single
cells of rare subpopulations within an enriched single cell suspen-
sion. After isolation, we performed whole genome amplification
(WGA) using the Ampli1TM WGA kit, which globally amplifies the
genome after generation of defined DNA fragments and adaptor liga-
tion using a single primer to the adaptor sequence.
With these three commercially available methods, we explored
the determinants of single CTC analysis and define quality criteria
for the diagnostic assessment of HER2 amplifications, PIK3CA muta-
tions and genomic copy number changes.
Results
Detection, isolation and whole genome amplification of CTCs
The aim of the study was to establish an experimental workflow
allowing reliable molecular single cell analysis in a clinical setting
within an acceptable time frame. The workflow allows interrupting
sample preparation at several steps, first, after cell enrichment and
detection and then after whole genome amplification of isolated
CTCs (Fig 1A).
To set up the workflow, we processed 79 CTC-positive Cell-
Search cartridges of 66 breast cancer patients provided by clinical
centers in Munich, Tübingen and Milan. Baseline characteristics of
the patients are shown in Table 1. After counting, we flushed Cell-
Search cartridges and loaded all cells into DEPArrayTM cartridges,
from which selected cells can be individually sorted into reaction
tubes. The overall CTC isolation efficiency is a result of several
steps, including extraction from the CellSearch cartridge, loading
onto and detection by the DEPArrayTM system as well as single cell
recovery. CellSearch CTC counts ranged from 1 to 892 CTC (mean
73.1, median 22, Supplementary Table S1). CTCs were re-detected
by DEPArrayTM using the standard CellSearch criteria to define a
CTC event, comprising (i) nearly round or oval morphology with a
visible nucleus within cytoplasm; (ii) staining profile (DAPI+/Cyto-
keratin+/CD45); and (iii) minimum diameter of 4 lm. To assess
the correlation between CellSearch CTC counts and DEPArrayTM
CTC re-detection, we had to account for a dead volume of the
DEPArray cartridges, as only 9.26 ll out of 14 ll total volume
injected were analyzed in the main chamber, that is, about two
thirds of the injected volume. In so doing, we found an excellent
correlation between the CellSearch CTC count and the DEPArrayTM
detection (Spearman’s rho correlation, n = 79, r = 0.94,
P < 0.00001, Fig 1B and Supplementary Table S1). Computing the
mean ratios of observed over expected CTCs (Supplementary Table
S1), we determined a mean transfer efficiency of 85% (median
77%, standard deviation  49%). Patient CTCs displayed hetero-
geneous morphology and staining intensity as in previous studies
(Allard et al, 2004) adding observer variability to the CellSearch–
DEPArrayTM comparison. Although we lost the CTCs of two
samples during the DEPArrayTM procedure (as expected from the
transfer efficiency), we found more CTC events than originally
detected with CellSearch in three cases. In all these cases, we
detected very small events with a diameter of 4 lm as determined
by DEPArrayTM, plausibly explaining why they were not counted in
the CellSearch enumeration.
We next assessed the routing efficiency, defined as the success
rate of displacing cells from the main chamber of the DEPArrayTM
chip into the parking chamber, where cells are collected before
flushing them into the reaction tube. Median routing efficiency was
94% (range 75–100%, interquartile range 9%) as assessed on a total
of 417 cells (246 CTC, 171 WBC) across 20 different experiments
comprising a range of 4–48 cells per experiment.
In total, we isolated 510 single CTCs of 64 breast cancer patients
and 189 single white blood cells (WBCs, defined as DAPI+/Cytoker-
atin/CD45+ cells) of 62 patients. The number of isolated single
cells per sample ranged from 1 to 68 cells (mean 7.3, median 6)
for CTCs and 1–18 cells (mean 2.6, median 2) for WBCs. Addition-
ally, we isolated 39 CTC pools of 21 patients (range 2–20 cells,
mean 6.4, median 5) and 77 WBC pools of 61 patients (range 2–73
cells, mean 10.8, median 6). Of all these samples, we amplified
the genomic DNA using the Ampli1TM WGA kit (Silicon
Biosystems SpA), which is based upon genome-wide Mse I diges-
tion (recognizing the sequence TTAA), ligation of a single adaptor
with unique sequence and PCR amplification (Klein et al, 1999,
2002).
Single cell recovery by DEPArrayTM and sample purity
To fully exploit molecular CTC analysis in a diagnostic workflow,
single cells should be isolated free from contaminating white blood
cells (WBCs). To assess the efficiency and purity of single cell recov-
ery by the DEPArrayTM system, we spiked cells of different tumor
cell lines (DLD1, MCF7, HCC-827 or SW480, respectively) into the
blood of healthy donors and analyzed the presence and identity of
isolated single cells by DNA fingerprinting (Ampli1TM STR kit). The
use of different genomes enabled us to unambiguously identify
contaminating DNA in every cell isolation and DNA preparation
experiment. During six independent consecutive DEPArrayTM sorting
experiments, we isolated 46 single tumor cells and 26 single WBCs
and were able to confirm cell presence in 69 of 72 (96%) of samples
by detection of STR bands. The failing three single-cell recoveries
were completely free of STR alleles. Most importantly, the DNA
fingerprint confirmed pure single cell recovery by showing the
expected genotype in 100% of recoveries (Fig 1C). Finally, genotyp-
ing was also applied to verify the absence of contaminating cells or
DNA in analyzing 9 blank (no-cell) recoveries used as internal
negative controls.
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Development of a quality control for
whole genome amplification
The quality of molecular data derived from whole genome amplifi-
cation (WGA) of single cells depends on the integrity of the input
DNA. To identify high-quality samples, we devised a test to assess a
reliable and comprehensive Ampli1TM whole genome amplification
(WGA) of single cell DNA. From our existing single cell WGA
biobank (with all samples prepared with the Ampli1 method), we
selected 72 WGA products of single disseminated cancer cells
(DCCs) isolated from bone marrow of breast and prostate cancer
patients, as well as from lymph nodes of melanoma patients. For
each of the three tumor types, we selected 12 DCCs that had been
successfully hybridized on human chromosomes in previous meta-
phase comparative genomic hybridization (mCGH) experiments
(n = 36) and 36 single DCC WGA libraries that had failed in mCGH
experiments (Fig 2A).
We next designed eight primer pairs for Mse I fragments located
on different chromosomal regions and with different Mse I fragment
length, ranging from 239 to 1936 bp (Supplementary Table S2). All
eight specific PCRs were performed on the 72 selected samples, and
we found three primer pairs that were associated with successful
mCGH experiments. Successful amplification of two out of three
or three out of three of these selected Mse I fragments showed a
A
B C
Figure 1. Detection, isolation and purity of single breast cancer CTCs.
A Flowchart summarizing the workflow for single CTC detection and molecular analysis. The boxes on the left depict analyses performed and methods developed
during the course of the study. The final workflow is shown in the middle column, and minimal turnaround time for the complete workflow is shown on the right
(assuming the blood drawn in the morning of day 1). Dashed lines indicate possible points of discontinuation during the workflow protocol.
B Correlation between expected (as calculated from CellSearch® CTC count) and observed (as per DEPArrayTM system) number of CTCs from 79 samples of 66 breast
cancer patients (Spearman’s rho correlation coefficient r = 0.94, P < 0.001).
C Genomic fingerprint analysis of DEPArrayTM isolated HCC827 cell line spiked in healthy donor blood. Allelic variants for three distinct genomic markers (D18S535,
D13S317 and D21S2039) included in Ampli1TM STR kit are shown for HCC827 single cell, HCC827 genomic DNA, donor WBC single cell and donor WBC genomic DNA.
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positive predictive value of 0.95 and 1.0, respectively (Fig 2A), for
successful karyotyping by mCGH. These three amplicons were then
validated using 100 diploid non-cancer cells that had been isolated
and their DNA amplified between 1999 and 2008. We selected 22
WGA products of single cells predicted to enable CGH analysis and
10 WGA products of single cells predicted to fail by the selected
three primer pairs. The performance of CGH was correctly predicted
in all 32 cases, resulting in a first quality control assay (QC1 assay).
We then isolated 88 single mononuclear cells from peripheral
blood of a male donor using a micromanipulator, amplified genomic
DNA using the Ampli1TM WGA kit and assessed the quality of ampli-
fication by the QC1 assay. We found that 83 of 88 (94.3%) of the
cells showed high DNA quality predictive of a successful metaphase
CGH experiment (Supplementary Table S3). For the remaining five
cells, we could not detect a single Mse fragment by QC1 indicating
loss of the cell during the isolation procedure.
For 22 positive WBC with three positive QC-PCRs, we then tested
the allelic discovery rate on few microsatellite and polymorphic loci
amenable for restriction length polymorphism analysis (five single
nucleotide polymorphisms and five microsatellite repeat polymor-
phisms). In total, we retrieved 407 of 440 (92.5%) of the 440 expected
single copy alleles, summing up to a call rate of 93.6% for microsatel-
lite markers and 91.4% for single nucleotide polymorphisms, respec-
tively (Supplementary Table S4). We concluded that the QC1 assay
identifies cells that are suited for comprehensive genome analysis
such as CGH and that enable high allelic discovery rates.
CTC morphology correlates with QC1 assay result
To assess the quality of clinical single cell WGA samples isolated
with our workflow, we first determined whether fixation, storage
and cell isolation during the CellSearch and DEPArrayTM procedures
influence WGA quality. We noted that, while 83 of 88 (94.3%)
Ampli1TM libraries of freshly isolated, unfixed mononuclear cells of a
healthy donor showed high DNA quality, only 124 of 189 (65.6%)
WGA libraries of single WBCs isolated from CellSearch/DEPArrayTM
cartridges had the same high DNA quality (chi-square, P < 0.00001,
Supplementary Table S3). Moreover, only 191 of 510 (37.5%) CTCs
displayed 2 of 3 or 3 of 3 fragments in QC1 (chi-square, P < 0.00001
for comparison with CellSearch-derived WBC, Supplementary Table
S3). While the lower DNA quality of fixed versus unfixed WBC most
likely reflects fixation or sample processing, the difference between
CTC and CellSearch-derived WBCs suggests biological rather than
technical underlying reasons.
We re-evaluated the CTC images of the DEPArrayTM Cell
Browser picture galleries to identify the underlying cause. Since
considerable disagreement exists about the correct identification of
individual CTC-like events among experienced operators of the
CellSearch system (Kraan et al, 2011), we grouped all CTC-like
events (defined by the CellSearch criteria mentioned above) into
four morphologically distinguishable subcategories. These CTC-like
events displayed morphologies from small particles of fragmented
cell-like appearance (subcategory I), small events with intact cellu-
lar morphology (subcategory II), and large events with irregular
cellular morphology (subcategory III) to intensely stained large
cells (subcategory IV, Fig 2B). We found CTCs from subcategory I
through IV in 23 (55%), 28 (67%), 27 (64%) and 19 (45%),
respectively, among 42 analyzed patients. We next correlated the
morphological subcategories with the QC1 assay result and
observed an increasing WGA quality from CTC subcategory I to
subcategory IV (chi-square, n = 283, P < 0.00001). Importantly,
CTCs from subcategory IV displayed similar QC1 results as single
WBC recovered from CellSearch cartridges (Fig 2B, Supplementary
Table S3).
QC2 multiplex PCR assay defines a cell genome integrity
index (GII)
Since breast cancer CTCs have been described as being frequently
apoptotic (Mehes et al, 2001) and since genomic DNA is fragmented
into small pieces of 180–200 bp length during Caspase-mediated
apoptosis (Wyllie, 1980), we tested Ampli1TM WGA products of 252
single CTC and 100 WBC for the presence of a short Mse I fragment
of 192 bp length (Supplementary Table S2). Interestingly, this Mse
fragment, encompassing the frequently mutated Codon12/13 of the
KRAS gene, was detected in 23 of 95 (24.2%) isolated single CTC
that had been negative for all QC1 assay fragments before, suggest-
ing that these samples contained cellular DNA, which may have
been damaged or degraded. Therefore, the non-random nature of
our amplification method enables to define a quality control assay
Table 1. Patient characteristics.
Variable Subcategory
CTC enumeration/7.5 ml
P-value*< 5 < 50 ≥ 50
Clinical stage Stage I–III (n = 8) 4 (50.0%) 4 (50.0%) 0 0.079
Stage IV (n = 56) 13 (23.2%) 22 (39.3%) 21 (37.5%)
Unknown (n = 2) 1 (50.0%) 0 1 (50.0%)
HER2 primary tumor Amplified (n = 10) 3 (30.0%) 4 (40.0%) 3 (30.0%) 0.958
Negative (n = 52) 14 (26.9%) 20 (38.5%) 18 (34.6%)
Unknown (n = 4) 1 (25.0%) 2 (50.0%) 1 (25.0%)
HR primary tumor Positive (n = 50) 11 (22.0%) 21 (42.0%) 18 (36.0%) 0.272
Negative (n = 14) 6 (42.9%) 5 (35.7%) 3 (21.4%)
Unknown (n = 2) 1 (50.0%) 0 1 (50.0%)
*Chi-square test, patients with unknown clinical stage, HER2 or HR status were not included in statistical analysis.
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consisting of four specific Mse I fragments that assess (i) whether a
cell has been successfully isolated (small fragment) and (ii) whether
the DNA has been fragmented prior to Mse I digestion (larger QC
fragments from the QC1 assay).
With this knowledge, we designed a four marker multiplex PCR
assay (QC2 assay), including the three primer pairs of the QC1
assay and primers for the KRAS fragment. This multiplex PCR
provides a genome integrity index (GII), defined by the detected
PCR bands as a measure for quality of each WGA sample generated
from an isolated single cell. GII values range from 0 (no band
detected) to 1 (only KRAS fragment detected), 2 (any one of the
three long Mse fragments detected), 3 (any two of the long Mse
fragments detected) and 4 (all three long Mse fragments detected)
(Fig 2C).
To validate our multiplex PCR assay, we next compared the
results from single marker PCRs of the QC1 with the multiplex
results of QC2. In total, 699 WGA samples from single cells had
been tested by QC1; of these, we could re-analyze 507 samples by
QC2 (Fig 2D). Multiplied by the number of analyzed markers with
both assays (n = 3; D5S2117, TP53 Ex2/3, CK19), this corresponds
to 1,521 evaluable PCR data points. In general, we found a very high
concordance between single-plex (QC1) and multiplex (QC2) PCR,
confirming 1,472 of 1,521 results (96.8%). However, in rare cases,
fragments detected by QC1 could not be detected by QC2 and vice
versa.
Performance of downstream molecular assays
For therapy decisions, knowledge about the mutational state of
specific target genes is essential. Furthermore, the karyotype of
isolated CTCs may become important. Therefore, we correlated
the GII with three different types of molecular single cell analyses
to assess its diagnostic utility, including (i) gene-specific point
mutation analysis (PIK3CA mutations in exon 9 and exon 20), (ii)
gene-specific quantification of copy number (ERBB2 (HER2) ampli-
fication) and (iii) genome-wide array CGH (aCGH). The number





Figure 2. Development of quality control assays for Ampli1TM WGA.
A Representative metaphase CGH experiments for successful (left panel) and failing hybridizations (right panel), which were used to identify the three discriminating
amplicons. Table summarizes assay performance for the selected primers.
B CTC subcategories according to size and morphology (examples for subcategory I-IV from left to right) are associated with the detection of the QC1 assay amplicons
(n = 289, chi-square, P < 0.00001).
C Gel picture of the multiplex PCR assay (QC2 assay). Lanes are loaded (left to right): size marker, MU01 CTC04 (GII 0), MU22 CTC01 (GII 2), MU32 CTC01 (GII 2), TB 04
(GII 0), MU28 CTC04 (GII 3), MU35 CTC04 (GII 4), MU12 CTC05 (GII 1), MU28 CTC03 (GII 3), MU35 CTC01 (GII 2), MU28 CTC02 (GII 4), PCR positive control, PCR negative
control, size marker.
D Summary of sample numbers tested for the different molecular assays.
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Analysis of small sequence changes or point mutations
The non-random nature of Ampli1TM WGA allows design of specific
primers for target sequences of interest based on the distribution of
the Mse I restriction-site motif TTAA. PIK3CA mutations cluster in
two hotspots in exon 9 and 20, which are located on genomic Mse I
fragments of 224 and 296 bp length, respectively. After Ampli1TM
WGA, these mutations are detected in single cells of cancer cell lines
with 100% sensitivity and with the expected allelic frequency of 1:1
(wild-type (wt) to mutated (mt)) in single MCF7 and 1:4 (wt:mt) in
T47D cells (Fig 3A and B). For clinical samples, targeted Sanger
sequencing worked best for high-quality WGAs (GII 3 or 4; chi-
square, n = 383, P < 0.00001, Table 2). However, point mutation
analysis often also worked with samples displaying a GII of 1 or 2
(up to 89% for PIK3CA exon 20; Table 2 and Supplementary Table
S5). Therefore, gene-specific assay performance clearly depends on
the length of the Mse I fragment under investigation.
We also addressed the occurrence of sequencing errors. From a
previous study, we took sequence data of 46 diploid cells analyzed
for 7 loci in TP53 gene by single-stranded conformational polymor-
phism method (Klein et al, 2002) and had not observed mutations
among 128,800 analyzed base pairs. Here, we analyzed 122 single
WBCs of 41 patients and 54 WBC pools of 45 patients for mutations
in PIK3CA exon 9 and 20 (for success rates in single cells, see
Supplementary Table S5). All samples showed wild-type sequence
for exon 9 and exon 20, with two exceptions: In one single WBC of






Figure 3. Assays for molecular single cell analysis.
A Exon 9 mutation E545K was detected in all single MCF-7 cells. The mutant allele is representing 45% of detected sequences averaged over all analyzed single cells
and 48% in genomic DNA of MCF7 (right). The horizontal red line indicates the allelic ratio of non-amplified genomic DNA.
B Exon 20 mutation H1047R was detected in all single T47D cells. The mutant allele is representing 80% of detected sequences averaged over all analyzed single cells,
as well as in genomic DNA. Cell 01 shows an allelic loss of the wild-type sequence. The horizontal red line indicates the allelic ratio of non-amplified genomic DNA.
C ERBB2 copy numbers were assessed by qPCR in 192 CTCs from breast cancer patients. Twenty-one single cells of 7 of 42 patients displayed an amplification
probability above 95% (indicated by the red horizontal line).
D ERBB2 amplification qPCR determined all single WBCs (n = 91) to be negative for ERBB2 amplification (below the red horizontal line).
E High-resolution aCGH profiles of four individual cells showing DNA loss (left), balanced aCGH profile (second from left), low copy number gain (second from right) and
high-level amplification (right) at ERBB2 locus (hybridization ratio for single probes shown on a log2 scale).
F ERBB2 copy number by aCGH correlates with amplification probability score by qPCR. A qPCR amplification probability score ≥ 0.95 (red horizontal line) indicates
ERBB2 amplification. Two samples dropped out of analysis due to failed amplification of qPCR fragments.
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mutational hotspot of exon 20, and we found a single WBC of
patient IB07 harboring a previously not described mutation at codon
1,015 resulting in the exchange of serin to tyrosine. From these data,
we estimate a mutation rate of 0.768 in 105 bases, within the range
of reported error rates for proof-reading polymerases.
Analysis of gene amplifications
In contrast to targeted sequencing, the applied qPCR assay to detect
gene amplifications is based on nine different amplicons: three on
the target gene, here ERBB2, and six on different reference loci.
Again, qPCR performed significantly better for GII 3 and 4 samples
(chi-square, n = 351, P < 0.00001; Table 2 and Supplementary
Table S4). The reproducibility of the assay was shown by high
correlation between results of technical replicates (Spearman’s rho
correlation, n = 27, r = 0.98, P < 0.00001), that is, amplification
status of all tested samples could be verified by qPCR repetition
(Supplementary Fig S1).
Genome-wide analysis of copy number alterations
Finally, we assessed applicability of whole-genome aCGH analysis
on single cell Ampli1TM WGA samples isolated by our workflow. We
first analyzed 10 single CellSearch/DEPArray-derived WBCs of nine
patients and noted a higher derivative log2 ratio spread (DLRS) in
our single WBC samples (mean 1.28, range 0.64–2.08), as compared
to previously published single cell aCGH experiments with unfixed
or mildly fixed cells (Czyz et al, 2014). The DLRS provides, among
other aspects, information about the global signal to noise levels in
a sample, with low values indicating better sample and hybridiza-
tion quality.
We therefore modified our analysis algorithm to address the
increase in DLRS. For CellSearch/DEPArray-derived CTCs, we
applied analysis settings that ensured that no artificial alterations
were called in CellSearch/DEPArrayTM-derived WBCs. This was
achieved at a resolution of 650 kb, where all analyzed single WBCs
displayed a balanced genomic profile (Supplementary Fig S2).
Applying these settings to CTCs, we noted that similar to targeted
sequencing and qPCR, clinical samples with high GII performed
better in whole-genome aCGH (chi-square, n = 50, P = 0.016,
Table 2).
To identify the underlying reason for the unexpected increase in
DLRS values, we isolated SKBR3 breast cancer cells either unfixed
or after CellSearch/DEPArrayTM isolation (for each treatment, three
single cells and one cell pool). Isolated cells were amplified by
Ampli1TM and analyzed by aCGH. We found higher DLRS in Cell-
Search treated as compared to unfixed single cells (0.73 and 1.12,
respectively), in line with our previous hypothesis that fixation
during CellSearch is influencing genomic integrity and thus perfor-
mance of Ampli1TM WGA. Nevertheless, genomic profiles of
untreated and CellSearch cells applying our algorithm are very simi-
lar and correspond to those of genomic DNA, although displaying
lower resolution (Supplementary Fig S3).
For cross-assay validation, we compared the measurement for
the ERBB2 locus obtained from qPCR and aCGH. ERBB2 amplifica-
tion was detected by qPCR in 21 of 192 single CTC (10.9%) but
never in WGA samples of 91 isolated single WBC (Fisher’s exact
test, P = 0.001; Fig 3C and D). We then categorized 47 samples
tested by aCGH into ERBB2 loss, balanced profile, low copy number
gain and high-level amplification of ERBB2 (Fig 3E). ERBB2 copy
numbers by aCGH matched with the qPCR amplification probability
score, with only two samples showing discordant results (Kruskal–
Wallis test, n = 43, P = 0.00002, Fig 3F).
Genome integrity index and patient stratification
In summary, we found that the GII as determined by QC2 assay
correlates with the performance of all molecular assays after single
cell isolation and Ampli1TM WGA. To determine how many patients
are suited for multiple molecular studies, we categorized the
patients into two groups. The first group comprises patients with
≥ 5 CTCs in 7.5 ml peripheral blood, which are at increased risk of
progression, and the second group patients with < 5 CTCs display-
ing lower risk of progression. From the first group, we could isolate
CTCs with GII 3 or 4 (high-quality DNA) in 68% patients, while
high-quality DNA samples could rarely be obtained from patients
with low CTC numbers (Fisher’s exact test, n = 74, P = 0.0019).
This difference is specific for CTCs, as WBCs (Table 3) performed
equally well in both groups.
Heterogeneity in metastatic breast cancer patients
Technical reliability is the sine qua non to investigate cancer cell
heterogeneity, which may underlie individual treatment responses.
Having firmly established the conditions of single cell analysis, we
proceeded to interrogate the potential impact of our findings.
In a first step, we analyzed 37 single CTC of 15 patients and
detected structural chromosomal changes in all analyzed CTC. The
detected genomic gains and losses are characteristic for breast
cancer (Fig 4A). Cluster analysis revealed patients with varying
degrees of clonal similarity. Of note, ERBB2-amplified CTCs
displayed little genome-wide heterogeneity (Figs 4B and 5A). To
investigate the impact of specific oncogenic mutations onto the




Genomic integrity index (GII)
P-value *GII 0 GII 1 GII 2 GII 3 GII 4
PIK3CA Exon 9 n = 383 7 of 23 (30.4%) 14 of 25 (56.0%) 48 of 62 (77.4%) 102 of 117 (87.2%) 146 of 156 (93.6%) < 0.00001
PIK3CA Exon 20 n = 383 8 of 23 (34.8%) 18 of 25 (72.0%) 55 of 62 (88.7%) 109 of 117 (93.2%) 149 of 156 (95.5%) < 0.00001
PIK3CA complete n = 383 4 of 23 (17.4%) 12 of 25 (48.0%) 45 of 62 (72.6%) 97 of 117 (82.9%) 141 of 156 (90.4%) < 0.00001
HER2 qPCR n = 351 3 of 12 (25.0%) 8 of 18 (50.0%) 41 of 61 (67.2%) 95 of 112 (84.8%) 136 of 148 (91.9%) < 0.00001
aCGH n = 50 Not assessed Not assessed 4 of 5 (80.0%) 7 of 9 (77.8%) 36 of 36 (100%) 0.016
*Chi-square test was used to confirm the correlation between performance of molecular assays with genome integrity index. Please note, for raw data on all
analyzed single cells see the Supplementary Dataset.
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genomic rearrangement of single CTCs, we compared the genomes
of cells with PIK3CA mutations and ERBB2 amplifications. We found
that PIK3CA-mutated CTCs do not differ from PIK3CA wild-type
CTCs regarding the frequency of copy number alterations (Mann–
Whitney U-test, n = 37, P = 0.478, Fig 4C), while ERBB2-amplified
CTCs displayed significantly higher numbers of genomic aberrations
than CTCs without ERBB2 amplification (Mann–Whitney U-test,
n = 37, P < 0.00001, Fig 4D).
This prompted us to have a closer look into the ERBB2-amplified
and PIK3CA-mutated CTCs. In total, 7 of 42 patients (16.7%)
displayed ERBB2 amplification in CTCs. Of these patients, all
analyzed single CTCs displayed the ERBB2 amplification with only
one exception indicating rare heterogeneity (14% of patients)
among CTCs for this specific aberration (Supplementary Fig S4).
However, when we compared the CTC findings with the ERBB2
status of the primary tumor, we noted that 8 of 40 (20%) patients
with available ERBB2 status of the primary tumor displayed dispar-
ity between CTCs and primary site for ERBB2 amplification (Fig 4E).
Moreover, of the 10 patients with ERBB2 changes in either the
primary tumor or the CTCs, eight patients (80%) displayed dispa-
rate ERBB2 amplification states.
We next analyzed the potential therapy target PIK3CA. We could
assess both PIK3CA mutational hot spots in 202 of 261 analyzed
CTCs (77.4%, Supplementary Table S5) and at least one of the two
exons in 241 of 261 (92.3%). Somatic mutations were detected in
54 of 202 CTCs (26.7%) resulting in 16 of 43 (37.2%) breast cancer
patients harboring mutated CTCs. Molecular heterogeneity among
PIK3CA-mutant CTCs was higher than for ERBB2-amplified CTCs
and detected in 10 of 16 patients (62.5%; Fig 5 and Supplementary
Table S6). For seven patients with mutated CTCs, we could addi-
tionally amplify CTC cell pools (2–14 cells). Among these samples,
the PIK3CA mutational status of the CTC pool matched the result of
the majority of single cells in six cases (four times mutated, two
times wild-type). Of note, in one patient (MU18) who harbored
three single CTCs with wild-type PIK3CA and one CTC with a
H1047R exon 20 mutation, the recovered CTC pool of 14 single cells
showed sequences of E545K exon 9 mutation (allelic ratio mt:
wt = 30:70; Supplementary Table S6).
Interestingly, CTCs of one individual patient may be heteroge-
neous for specific mutations, and may be associated with character-
istic genomic rearrangements. Of four patients, we analyzed pools
of CTCs by aCGH in addition to single CTC samples. Genomic
profiles of CTC pools corresponded well with single cell data and
confirmed the high clonal relationship between individual CTCs.
However, in one patient with 409 CTC in 7.5 ml of blood (MU27),
we detected the M1043V mutation in exon 20 of PIK3CA in the CTC
pool and all but one single CTC. Strikingly, this specific PIK3CA-
wild-type CTC displayed different genomic aberrations than all other
analyzed CTCs (Fig 5B).
Finally, CTCs of 2 of 7 (28.6%) patients with ERBB2 amplifica-
tion in CTCs also displayed PIK3CA mutations (Fig 4F and Supple-
mentary Fig S4). Assessing the PIK3CA mutational status for
matched primary tumors and CTCs of six patients, we found a
disparity of 66% (Fig 4G). When the combined status of ERBB2 and
PIK3CA was assessed for these individual pairs, only 1 of 6 pairs
displayed identical patterns in primary tumors and CTCs (Fig 4G).
Discussion
Here, we provide a workflow for the molecular characterization of
CTCs that enables reliable analysis of single cells for diagnostic
purposes. We addressed the diagnostic needs of faithful detection of
mutations, selected gene amplifications and genome-wide copy
number alterations in CTCs by combining the CellSearch system for
CTC enrichment with an automated cell isolation method, the
DEPArrayTM technology, and the non-random Ampli1TM WGA
method. Importantly, the developed single cell isolation and molec-
ular analysis workflow is not restricted to CellSearch enrichment
but can easily be applied to other methods which are able to enrich
CTCs and provide a cell suspension.
Currently, clinicaltrials.gov lists more than 260 studies, which
explore the utility of CTC detection, enumeration and targeted
molecular analysis. There is substantial hope that CTC analysis will
help to monitor disease progression, predict response to selected
drugs and identify therapy-resistant cancer early on. Hence, there is
a great medical need to provide a diagnostic workflow that enables
clinical decision-making based on few available cancer cells. By all
available technologies, the number of CTCs in cancer patients is
very low, although some partially conflicting results have been
reported. Perhaps, the most reliable data have been provided by the
CellSearch system (Cristofanilli et al, 2004) and analysis of diagnos-
tic leukapheresis samples (Fischer et al, 2013). The CellSearch
system is the only FDA-cleared CTC detection and enumeration
device currently available and has therefore been used in the major-
ity of studies. Its usefulness in breast cancer has been firmly estab-
lished (Bidard et al, 2014), although its dependence on positive
selection of EpCAM-positive CTCs may lead to false-negative or
false-low CTC results in some patients (Sieuwerts et al, 2009).
By enrichment-independent analysis of leukapheresis samples,
however, it was shown that CTC numbers are generally low ranging
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from 1 to 15 cells per ml of blood (Fischer et al, 2013) at least for
breast cancer. This upper level of CTC numbers suggests that stan-
dard molecular methods established for thousands to millions of
cells need to be adjusted to few or even single cells, if molecular
information needs to be obtained.
CTC analysis is likely to become complementary to primary
tumor analysis the more disease courses are prolonged by therapy.
Molecular diversity among tumor cells has been recognized as a
major driving force for evolution of an individual cancer (Greaves &
Maley, 2012; Klein, 2013) and takes largely place outside the
primary tumour. Today, metastasis frequently arises years after
excision of the primary in many breast cancer patients and most
metastatic patients experience multiple lines of systemic therapies.
The applied iatrogenic selection leads to survival of tumor cells
with acquired resistance, one example being ESR1 mutations under
antihormonal therapy (Toy et al, 2013). Therefore, the medical need
to re-evaluate the molecular profiles of remnant cancer cells is likely
to grow with the number of therapeutic options.
Characteristics of the established workflow
We consequently established and explored a full diagnostic work-
flow from cell detection to molecular characterization. This work-
flow can be easily integrated into clinical studies, because it enables
several points of discontinuation without loss of information. After
CellSearch detection, cartridges can be stored before transfer to the
DEPArray for at least 3 weeks. Then, after isolation and WGA, DNA
samples can be stored for several years (Czyz et al, 2014). More
specifically, we found that we can morphologically pre-select CTCs





Figure 4. Molecular heterogeneity of breast cancer CTCs.
A Chromosomal aberrations in 37 single CTCs of 15 breast cancer patients. The histogram plot displays the frequency of genomic gains (red) and losses (green) of
CTCs, which are characteristic for breast cancer cells.
B Unsupervised hierarchical cluster analysis using the average linkage mode of breast cancer patients with more than one analyzed CTC (34 cells of 12 patients).
Distances of vertical lines to the next branching point in dendrogram represent relatedness. Red vertical lines indicate that all analyzed CTCs of an individual
patient are located within the same branch of the dendrogram.
C, D Number of chromosomal changes in PIK3CA-mutated (C) and ERBB2-amplified (D) versus wild-type CTCs. Note that CTCs with ERBB2 amplification showed a
significantly higher number of genomic aberrations than CTCs without amplification (n = 37, Mann–Whitney U-test, P < 0.00001).
E ERBB2 status in CTCs versus ERBB2 status in primary tumors in individual pairs.
F PIK3CA mutational state and ERBB2 copy number gains in CTC of individual patients.
G Paired analysis of mutational states for PIK3CA and ERBB2 of primary tumors versus matched CTCs of six patients. Note that only patient MU16 displays shared
states in primary tumors and CTCs.
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round CTCs gave rise to excellent molecular results similar to single
WBCs, while small and irregularly formed CTCs may represent
damaged cells. We uncovered this association because we had devel-
oped a simple PCR-based quality control (QC) assay for Ampli1TM
WGA products that predicted the outcome of downstream molecular
studies. The genomic integrity index (GII) deduced from this QC assay
classifies all isolated cells into four categories, with cells from catego-
ries 3 and 4 being optimally suited for further characterization.
The use of the workflow within clinical studies is further
supported by the high information retrieval from rare events. We
A
B
Figure 5. Genomic profiles of single breast cancer CTCs.
A Genomic overview over four isolated single breast CTCs with ERBB2 amplification (patient MU37). All CTCs of patient MU37 show high number of chromosomal
aberrations and high clonality in their genomic profile. ERBB2 high-level amplification for all CTCs was validated by qPCR assay (aberration calls depicted on y-axis in
log-2 scale).
B Genomic overview over four isolated single breast CTCs and a CTC pool from patient MU27. Three of four CTCs show highly similar genomes and M1043V mutations
in exon 20 of PIK3CA as the analyzed CTC pool (blue profiles). However, one CTC (CTC06, red profile) displays several different chromosomal aberrations (aberration
calls depicted on y-axis in log-2 scale) and lacks the M1043V mutation.
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validated the successful transfer of detected CTCs from the
CellSearch to the DEPArrayTM system and isolation into the reaction
tube. Transfer efficiency was 85% and isolation efficiency 94%,
resulting in a success rate of 80% that a detected CTC can be molec-
ularly explored. Factors determining whether or not the isolated cell
will provide high-quality molecular information were tested next.
First, cell fixation reduced the percentage of high-quality DNA
samples obtained from normal diploid WBCs from 94 to 66% and
increased the noise in array CGH experiments. Second, the GII of
CTCs was shifted to lower values compared to WBCs with about
38% of CTCs generating high-quality DNA samples. This indicates
that a substantial proportion of CTCs are damaged or apoptotic as
suggested previously (Mehes et al, 2001). Consequently, it was
more difficult to generate high-quality DNA samples from patients
with < 5 CTCs than from patients with ≥ 5 CTCs. In total, we esti-
mate that samples with ≥ 3 CTCs will enable successful molecular
characterization of at least one CTC (0.85 × 0.94 × 0.375). From
our patient cohort, we isolated high-quality CTCs from 57% of
patients.
The ability to establish the QC assay and the strong correlation
between WGA and downstream molecular assays is clearly linked to
the deterministic nature of the Ampli1TM WGA assay (Klein et al,
1999), which has been tested extensively in previous studies using
patient samples (Klein et al, 2002; Schmidt-Kittler et al, 2003;
Schardt et al, 2005; Weckermann et al, 2009; Fischer et al, 2013;
Ulmer et al, 2014). The method has several advantages over single
cell amplification methods that employ random priming such as
DOP (Telenius et al, 1992) or PEP (Zhang et al, 1992), MALBAC
(Zong et al, 2012) or multiple strand displacement (Hou et al,
2012). For Ampli1TM WGA, the genome is cut at the restriction-site
TTAA. Therefore, selected amplicons will be amplified equally in all
single cells of all patients, with minor differences among individuals
due to polymorphisms in the TTAA motif. CTCs from GII categories
3 and 4 were positive for TTAA-fragments of PIK3CA and KRAS in
more than 90% of cells. CTCs from GII category 1 and 2 may still
provide valuable information for mutations in selected genes. For
example, more than 50% of cells with GII 2 are suited for analysis
of amplicons harboring the hot spot regions of PIK3CA exon 9 and
exon 20. Likewise, assays for therapy relevant copy number altera-
tions can be easily designed (similar to ERBB2 locus investigated
here) and enable faithful analysis of > 90% CTCs from GII
categories 3 and 4. This is in stark contrast to other methods that
display allelic discovery rates of about 70% or less (Zong et al,
2012). The downside of Ampli1TM is that some loci may be less
easily accessible if the TTAA-fragments become either too large
or too small. However, even this disadvantage can be predicted
from DNA sequences of interest and can be overcome easily by
selection of a different restriction enzyme for a specific diagnostic
question.
Reliable assessment of single CTCs for combined genetic altera-
tions is unique to approaches that analyze individual cells. Unlike
other approaches that display low purity of isolated cells (Nagrath
et al, 2007; Yu et al, 2012), we could show by DNA fingerprinting
analysis of spike-in experiments that we were able to isolate and
amplify genomic DNA of 96% of isolated single cells with 100%
purity. Methods that amplify DNA or RNA of CTCs within a back-
ground of contaminating normal cells, such as WBCs (Nagrath et al,
2007; Yu et al, 2012), or other CTCs (Magbanua et al, 2012, 2013),
or methods that rely on the analysis of circulating nucleic acids
(Schwarzenbach et al, 2011) will not retrieve cellular combinations
of alterations with diagnostic precision.
Molecular findings in clinical samples
For the first time, we confirmed the malignant origin for all individ-
ually isolated breast cancer CTCs. Previous studies investigated
pools of cells (Magbanua et al, 2012, 2013) or identified cells as
aberrant or normal for selected molecular markers (Lowes & Allan,
2014). Since the cell selection for aCGH was only based on the GII,
we conclude that CellSearch criteria-positive and GII-high cells from
M1 stage breast cancer patients are indeed CTCs.
In cancer, the unit of selection is the individual cancer cell, and
hence, we expect most insight into drug resistance by comparative
studies on purified individual CTCs before and after administration
of a drug. The potential use of this reasoning is exemplified by our
analysis of ERBB2 and PIK3CA alterations. For the PIK3CA and
ERBB2 alterations, we determined the reliability of both assays to
be > 90% for GII 3 and 4 cells. Because assay-related single cell
variation will multiply its negative effects, the more genomic loci
of a cell are investigated, such a high reliability of each assay
was needed to demonstrate combined alterations of the two genes.
In our cohort, we identified 2 out of 7 patients with ERBB2
amplification-harboring CTCs who had double-mutant PIK3CA/
ERBB2 CTCs prior to administration of ERBB2-targeting therapies.
This is of interest as somatic mutations in PIK3CA were shown to
be associated with resistance against ERBB2-targeted therapies
(Berns et al, 2007; Chandarlapaty et al, 2012) and significantly
worse outcome in ERBB2-positive patients (Cizkova et al, 2013).
Since first studies demonstrate efficacy of PIK3CA pathway
inhibitors for these patients (Janku et al, 2012), prior assessment
of pre-existing resistant cells may become useful. Furthermore, we
found that for one individual patient, both PIK3CA hot spot
mutations may co-exist in different cells, providing further
compelling evidence for independent and parallel acquisition of
driver mutations by individual cancer cells.
Insights into the molecular evolution of systemic cancer
Our data show that single cell analysis will enable a better under-
standing of cancer evolution. Measures of cellular diversity or
evolutionary state are a novel form of biomarker, which are increas-
ingly recognized (Maley et al, 2006; Park et al, 2010) but have only
recently been applied to metastasis research (Almendro et al, 2014).
Evidence is growing that disseminated cancer cells continue to accu-
mulate alterations outside the primary tumor (Schmidt-Kittler et al,
2003; Weckermann et al, 2009; Klein, 2013) and that the number of
genetic alterations in single CTCs is associated with shortened
survival (Fischer et al, 2013). For our patients, we identified 14% of
patients with ERBB2-negative primary tumors harboring ERBB2-
positive CTCs and a disparity in 66% of individual primary tumor–
CTC pairs for PIK3CA mutations. In only 1 out of 6 patients, CTCs
shared the mutational state of the oncogenes ERBB2 and PIK3CA
with the primary tumor. As we did not apply subclone analysis on
primary tumor samples, we cannot exclude the existence of CTC-
associated mutations that are detected in a minority of primary
tumor cells, as it has been suggested by recent sequencing studies of
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primary tumors revealing molecular heterogeneity of different
subclones within individual tumors (Gerlinger et al, 2012).
However, it is noteworthy that we found in most cases ERBB2
amplifications to be shared homogeneously among analyzed CTCs
of individual patients. Consequently, if cells with this specific alter-
ation previously represented a minor subclone within the primary
tumor, they had now turned into the predominant clone outside the
primary tumor. This suggests that some driver mutations, acquired
within or outside the primary tumor, confer selective advantages for
survival and expansion of cancer cells outside the primary tumor.
We also observed that the degree of genomic rearrangement of a
cell is associated with specific driver mutations. ERBB2-amplified
CTCs displayed higher numbers of genomic alterations than ERBB2-
negative CTCs, whereas no such effect was seen for PIK3CA muta-
tions. Whether the pronounced clonality of ERBB2-amplified CTCs
from ERBB2-negative primary tumors suggests strong oncogene
addiction must await further exploration. However, the findings
demonstrate that molecular analysis of individual CTCs may uncover
evolutionary mechanisms useful for personalized therapy decisions.
Last but not least, CTC characterization with diagnostic precision
as described here may provide an answer to the outcome of the
SWOG S0500 trial, where CTC enumeration was shown not to be
sufficient to inform on alternative chemotherapeutic treatments
(Smerage et al, 2014). Only molecular CTC analysis linked to targeted
therapies may thus represent the means to bring the concept of
liquid biopsy to clinical success.
Materials and Methods
Patients and CTC enrichment and detection using the
CellSearch® assay
Enrichment and detection of CTCs was performed within the
SUCCESS (EUDRA-CT number 2005-000490-21) and DETECT
(EUDRA-CT number 2010-024238-46) (Fehm et al, 2010) studies using
the CellSearch system (Riethdorf et al, 2007) and within various
studies exploring the role of CTCs at the European Institute of
Oncology in Milan between August 2011 and August 2012. Written
informed consent for CTC analysis and characterization was
obtained for all patients included. All experiments conformed to the
principles set out in the WMA Declaration of Helsinki and were
approved by the ethical committees responsible for the correspond-
ing studies (Universities of Munich, Dusseldorf, Ulm, and European
Institute of Oncology, Milan).
One up to three 7.5-ml blood samples were collected into CellSave
tubes (Veridex Inc.). The CellSearch Epithelial Cell Test (Veridex
Inc.) was applied for CTC enrichment and enumeration according to
the instruction from the manufacturer. In brief, CTCs are captured
from peripheral blood by anti-epithelial cell adhesion molecule
(EpCAM)-antibody-bearing ferrofluid and subsequently checked for
positivity or negativity for cytokeratin, the leukocyte common anti-
gen CD45 and 40,6-diamidino-2-phenylindole (DAPI) staining to
ensure the integrity of the nucleus. Samples from the SUCCESS study
were prepared using a slightly modified protocol. Here, peripheral
blood was drawn into three separate CellSave tubes (30 ml). The
samples were shipped at room temperature to the central cancer
immunological laboratory at the University of Munich and analyzed
within 96 h of blood sampling. The 30-ml blood samples were centri-
fuged for 10 min at 800 × g. The plasma was removed, and a dilu-
tion buffer was added as described. This mixture was overlaid on
6 ml of Histopaque (Sigma, Germany) and centrifuged for 10 min at
400 × g. Subsequently, 7.5 ml of this sample containing the buffy
coat was processed on the CellTracks AutoPrep system using the
CellSearch Epithelial Cell kit (Veridex, USA).
To setup this proof-of-principle study, only CTC-positive
cartridges were sent from Munich and Tübingen to Regensburg for
cell isolation and mutational analysis (ethics vote number 07-079).
Cartridges analyzed by Silicon Biosystems were obtained from the
European Institute of Oncology, Milan. Although in clinical studies,
only CellSearch cartridges with at least 5 CTC/7.5 ml of blood are
counted as positive, 15 samples with < 5 CTC/7.5 ml were included
into this study to better evaluate the workflow.
Isolation of CTCs and WBC by DEPArray
Cells were extracted from CellSearch cartridge using a 200 ll gel-tip
pre-rinsed in PBS-BSA 2% and transferred to a new protein LoBind
1.5-ml tube (Eppendorf, Germany). Subsequently, the cartridge was
washed two times using 325 ll of SB115 Buffer (Silicon Biosystems
SpA, Italy) and repeatedly pipetting against the inner surface. The
complete fluid was transferred to the 1.5-ml sample tube. After centri-
fugation at 1,000 g for 5 min in a swinging-bucket rotor centrifuge, the
supernatant was discarded, 1 ml of SB115 Buffer was added, and the
tube was again centrifuged at 1,000 g for 5 min in a swinging-bucket
rotor centrifuge. The supernatant was withdrawn, and the pellet was
resuspended in a final volume of 14 ll SB115 Buffer.
Next, the sample was loaded on a DEPArrayTM chip and scanned
for CTC to isolate cells for molecular analysis according to the
manufacturer’s protocol. Cell suspensions from ten cartridges of
individual patients with high CTC counts were split into two or
more aliquots in order to increase the number of recoveries. This
was initially necessary as the number of single cell recoveries was
limited to 16–18, while the current version of the DEPArrayTM allows
up to 35 recoveries per run. Recovery of a single cell by DEPArrayTM
system takes 8–10 min. The current version of the system needs
about 3 min for a single cell recovery.
In order to reduce the collected volume of 18 ll SB115 Buffer to
1 ll of PBS required for Ampli1TM WGA, tubes containing recovered
single cells were centrifuged at 14,100 g for 30 s in a fixed rotor
centrifuge. 100 ll of 1× PBS was added without disturbing the
sample, and tubes were centrifuged at 14,100 g for 10 min in a fixed
rotor centrifuge. To reach the final volume of 1–2 ll containing the
isolated cell, a 200-ll pipette with its tip pointing to the tube wall
opposite to the centrifugation direction was used. The buffer was
aspirated carefully while sliding the tip on the tube wall and follow-
ing the air-liquid meniscus toward the tube bottom without dipping
the tip.
Ampli1TM whole genome amplification
DNA of isolated cells was amplified using the Ampli1TM kit (Silicon
Biosystems) according to the recommendations of the manufacturer
resulting in 50 ll of WGA product. The method is based on a
published adaptor-ligation-mediated whole genome amplification
protocol (Klein et al, 1999, 2002).
EMBO Molecular Medicine Vol 6 | No 11 | 2014 ª 2014 The Authors
EMBO Molecular Medicine Molecular profiling of circulating tumor cells Bernhard Polzer et al
1382
DNA fingerprinting of Ampli1TM WGA samples
DNA fingerprinting using short tandem repeat (STR) was carried out
using an STR-based assay, encompassing a multiplex PCR with 11
loci compatible with Ampli1TM WGA digest according to the manu-
facturer’s manual (Ampli1TM STR kit, Silicon Biosystems, Spa). STR
analysis was used to confirm purity of isolated single cells Ampli1TM
WGA DNA libraries in spiking experiments and additionally used to
exclude exogenous DNA in blank controls of patient samples.
Ampli1TM WGA quality control assays (QC1 and QC2 assay)
Single marker PCRs for detection of 8 specific Mse fragments for the
development of QC1 assay were conducted as previously described
(Schardt et al, 2005). For all PCRs, 0.5 ll WGA product was used as
template; oligonucleotide sequences and corresponding annealing
temperature TA are listed in Supplementary Table S2. Single cell
metaphase CGH was done according to Klein et al (2002, 1999) to
validate the selected primer pairs for the QC1 assay.
For the multiplex PCR (QC2 assay), 1 ll WGA template was used
in 10 ll of a water-based mastermix containing 1× FastStart PCR
Buffer (including MgCl2), 200 nM dNTPs, 0.5 U FastStart Taq Poly-
merase and 4 lg BSA (all consumables Roche Diagnostics GmbH,
Germany). The eight primers of QC2 assay (KRAS, D5S2117, TP 53
Exon 2/3 and CK19, see Supplementary Table S2) were each used
in an end concentration of 0.4 lM. PCR was started with a first step
at 95°C for 4 min, followed by 32 cycles of 95°C for 30 s, 58°C for
30 s and 72°C for 90 s, and a final elongation step of 7 min at 72°C.
To determine the genome integrity index, PCR products were visual-
ized on a 1.5% agarose gel. The protocol of the multiplex PCR assay
is the basis for the now commercially available Ampli1TM QC kit
(Silicon Biosystems spa).
ERBB2 qPCR assay and PIK3CA sequencing of single cells
To assess ERBB2 copy number changes, we modified the assay
described by Schardt et al (2005). Briefly, we assessed the abun-
dance of three Mse fragments from the genomic location of the
target gene of interest (here ERBB2) by quantitative PCR (qPCR).
Additionally, qPCRs were performed with additional primer pairs
amplifying six reference genes which are located on different chro-
mosomes and in regions with relatively rare copy number changes
in single DCCs of various cancers. Quantitative PCR (qPCR) was
performed using a LightCycler 480 (Roche, Mannheim, Germany)
and Fast Start Master SYBR Green I Kits (Roche) using 1 lL of
primary PCR products from the whole genome amplification diluted
1:100 in H2O. The reaction was performed in LightCycler 480 Multi-
well Plates 96 (Roche), with a primer concentration of 0.4 mM.
Relative quantification analysis was done using the LightCycler 480
software release 1.5.0 (Roche). qPCR was carried out as follows:
pre-incubation at 95°C for 5 min, followed by 38 cycles of amplifica-
tion at 95°C for 20 s, annealing for 15 s at the specified temperature
of the corresponding primer pair (Supplementary Table S7) and 15 s
at 72°C. Melting curve analysis was carried out between 50 and
95°C with five acquisitions per °C. A previously established external
standard curve was used to calculate the PCR efficiency for each
primer pair. Measurements showing unspecific products in the melt-
ing curve analysis were discarded from further statistical analysis.
All samples were run in duplicates and only included into the addi-
tive model if they had at least two of three successful measurements
of the target and four of six successful measurements of the refer-
ences.
The LightCycler software provided calibrated ratios of target and
reference qPCR values according to Pfaffl (2001). For all qPCR reac-
tions, the same calibrator, consisting of pooled single cells, was
used. Using three targets and six references resulted in 18 pairwise
ratios per sample that were subsequently transformed to the log2
scale. From these values, qPCR summary statistics were computed
using the “median polish” method. The obtained result was statisti-
cally compared to the normal distribution of values obtained by the
measurement of 130 WGA-amplified diploid single cells. Amplifica-
tion probability was defined as one minus the type I error for classi-
fying a normal control cell as being amplified. The resulting score
ranges from 0 to 1, and an amplification probability of 0.95 or
higher defined the tested cell as amplified for ERBB2. All statistical
analyses were performed using the R programming language
(R-Development-Core-Team, 2011).
PIK3CA mutation was assessed by Ampli1TM PIK3CA Seq kit (Sili-
con Biosystems spa) on single cells following Ampli1TM WGA. For
each PIK3CA exon, 1 ll of WGA product was used for the PCR.
Resulting PCR products were loaded on a 1.5% agarose gel, and
positive samples were purified using QIAquick purification kit
(Qiagen, Germany) according to the manufacturer’s protocol with
the exception that eluation at the end of the protocol was in 25.0 ll
water. Purified samples and primers were then sent to a sequencing
provider (Sequiserve, Vaterstetten, Germany). Negative PCR results
were considered dropouts for PIK3CA analysis.
Single cell aCGH analysis
For whole-genome analysis, we applied a recently established
protocol for aCGH of Ampli1TM products from single cells (Czyz
et al, 2014). Briefly, Ampli1TM WGA product is re-amplified three
times independently (each 1 ll of Ampli1TM product in 50 ll reac-
tion volume), and re-amplification products are pooled after qual-
ity control by Ampli1TM QC kit. Then, each WGA product is
labeled with fluorescence dye-conjugated dCTP and dUTP by two
independent PCRs (Cy3 for test and Cy5 for reference sample). As
a reference, we used four re-amplified high-quality WGA products
of single diploid lymphocytes of a female healthy donor that were
pooled. The two labeling reactions (test and reference) are pooled
and purified using Amicon Ultra 0.5 columns. DNA yields
and dye incorporation rates were quantified using the NanoDrop
ND-1000.
Array CGH was performed on oligonucleotide-based SurePrint
G3 Human CGH 4 × 180K microarray slides (design code: 022060)
according the protocol provided by the manufacturer (Agilent
Oligonucleotide Array-Based CGH for Genomic DNA Analysis,
version 7.1, December 2011) with slight modifications (Czyz et al,
2014). Finally, slides were scanned using an Agilent Microarray
Scanner Type C, and images were processed with Agilent Genomic
Feature Extraction Software (version 10.7) and imported and
analyzed with Agilent Genomic Workbench Software (version 6.5
lite). For defining aberrant regions, we used the ADM-2 algorithm
with threshold set to 7.0 and a centralization of 6.0. To avoid
false-positive calls, the minimal number of probes in an aberrant
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interval was set to 50 probes and minimum log2 ratio to 0.25.
Considering the average spacing of probes on the microarrays
(13 kb), the mean size of detectable genomic aberrations is there-
fore estimated to be 650 kb.
All data have been deposited in NCBIs Gene Expression Omnibus
(GEO, http://www.ncbi.nlm.nih.gov/geo/) and assigned series
accession number GSE58192.
Data evaluation
All statistics were calculated using IBM SPSS Statistics 20 for
Windows. Statistical significance was assumed for P < 0.05, with all
tests performed two-sided. For aCGH evaluation, we used the ADM-2
algorithm of the Agilent Genomic Workbench software.
Supplementary information for this article is available online:
http://embomolmed.embopress.org
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